Y-mAbs Announces Update on Naxitamab and Omburtamab in Neuroblastoma 16 October 2020
Y-mAbs, a late-stage clinical biopharmaceutical company focused on the development and commercialization... Read more
Y-mAbs, a late-stage clinical biopharmaceutical company focused on the development and commercialization... Read more
Read the entire insert here and the article with Hans Shambye here. >>
Y-mAbs Therapeutics, Inc., a late-stage clinical biopharmaceutical company focused on the development... Read more
Y-mAbs Therapeutics, Inc., a late-stage clinical biopharmaceutical company focused on the development... Read more
For our Danish readers, please enjoy the Life Science section of Berlingske today 15th Sept 2020, where... Read more
European start-ups selected as part of a joint initiative with J&J and the US government Did you... Read more
MC2 Therapeutics, a commercial stage pharmaceutical company focused on innovative topical therapies for... Read more
Y-mAbs Therapeutics, Inc., a late-stage clinical biopharmaceutical company focused on the development... Read more
Y-mAbs Therapeutics, Inc., a late-stage clinical biopharmaceutical company focused on the development... Read more